Loading
Life sciences · Interventional Study
ClinicalTrials.gov · November 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06526195). This is a study registration, not published results. Lead sponsor: Abbott Medical Devices. Recruitment status: RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 850 participants (ESTIMATED). Conditions: Heart Failure, Heart Diseases, Cardiovascular Diseases, Pulmonary Hypertension. Interventions: DEVICE: CardioMEMS HF System; DEVICE: HeartMate 3 Left Ventricular Assist System; OTHER: Guideline Medical Directed Therapy. Primary outcome measures: Survival at 2 years free of disabling stroke, reoperation to replace the device, or worsening HF requiring listing for urgent heart transplantation or mechanical circulatory support, enrollment into hospice, or dependence on IV inotropes , 2 years. Brief summary: The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.